MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster ...

Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced the acceptance of multiple abstracts for presentation at three significant upcoming congresses focusing on angioedema, ...

A PowerPoint abstract is a complete and concise description of research summarized in a document and intended for a slide presentation. There are four basic components to abstract writing. There is ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO ...

Arbutus Biopharma Corporation announced that five abstracts, including a late-breaker, have been accepted for poster presentations at the EASL Congress 2025 in Amsterdam from May 7 to 10, 2025. The ...

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the ...

A lightning talk is a very short presentation on a timely topic of interest to the audience. Lightning talks are 2-3 minutes with just 1-2 slides, followed by a group discussion. The main goals of the ...

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in ...